| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 10.02.
| Bristol-Myers, SNY Win Plavix Damages | | 2 | Zacks |
| 08.02.
| Bristol-Myers Squibb to Present at Leerink Swann 2012 Global Healthcare Conference | | 81 | Business Wire |
| Bristol-Myers
Squibb Company (NYSE: BMY) will present at the Leerink Swann 2012
Global Healthcare Conference Wednesday, February 15, 2012, in New York. Beatrice
...
Mehr lesen zu:
Bristol-Myers Squibb to Present at Leerink Swann 2012 Global Healthcare Conference | |
| 08.02.
| Watch for Shares of Bristol-Myers Squibb to Approach Support at $31.93 | | 1 | SmarTrend |
| 08.02.
| From Earlier: Sanofi and Bristol-Myers Squibb Collect Damages in Plavix Patent Litigation with Apotex | | - | Benzinga.com |
| 08.02.
| Sanofi (SNY), Bristol-Myers Squibb (BMY) Get $442.2M Payment from Plavix Settlement | | 3 | StreetInsider.com |
| 08.02.
| Sanofi, Bristol-Myers Collect Damages In Plavix Patent Litigation With Apotex | | 66 | AFX News |
| PARIS (dpa-AFX) - Sanofi (SNY, SNYNF.PK) and Bristol-Myers Squibb Co. (BMY)
said Apotex has made payment in the amount of $442.21 million to Sanofi and
Bristol-Myers Squibb to satisfy the...
Mehr lesen zu:
Sanofi, Bristol-Myers Collect Damages In Plavix Patent Litigation With Apotex | |
| 08.02.
| Sanofi and Bristol-Myers Squibb Collect Damages in Plavix Patent Litigation with Apotex | | 50 | Business Wire |
| Sanofi
(EURONEXT: SAN and NYSE: SNY) and Bristol-Myers
Squibb Company (NYSE: BMY) announced today that Apotex has made
payment in the amount of $442,209,362 to...
Mehr lesen zu:
Sanofi and Bristol-Myers Squibb Collect Damages in Plavix Patent Litigation with Apotex | |
| 06.02.
| Earnings Scorecard: Bristol-Myers | | 2 | Zacks |
| 06.02.
| BRISTOL MYERS - Das ist nun aber grenzwertig | | 12 | GodmodeTrader.de |
| 03.02.
| Bristol-Myers: Hart-Scott-Rodino Waiting Period For Inhibitex Purchase Expired | | 61 | AFX News |
| NEW YORK CITY (dpa-AFX) - Bristol-Myers Squibb Co. (BMY) said that the
waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as
amended for its tender offer for Inhibitex...
Mehr lesen zu:
Bristol-Myers: Hart-Scott-Rodino Waiting Period For Inhibitex Purchase Expired | |
| 03.02.
| Bristol-Myers Squibb (BMY) Moves One Step Closer to Completing Inhibitex (INHX) Acquisition | | 6 | StreetInsider.com |
| 03.02.
| Bristol-Myers Squibb Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Inhibitex | | - | Benzinga.com |
| 03.02.
| Bristol-Myers Squibb Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Inhibitex, Inc. | | 39 | Business Wire |
| Bristol-Myers Squibb Company (NYSE: BMY) announced today that the
waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of
1976, as amended (HSR) for its...
Mehr lesen zu:
Bristol-Myers Squibb Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Inhibitex, Inc. | |
| 01.02.
| XETR FFM:New Instruments available on XETRA - 01.02.2012-001 | | 317 | Xetra Newsboard |
| The following instruments on XETRA do have their first trading day 01.02.2012 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag am 01.02.2012 TrdMod InstCode Exch ISIN Name InstGrp...
Mehr lesen zu:
XETR FFM:New Instruments available on XETRA - 01.02.2012-001 | |
| 31.01.
| Is Bristol-Myers Squibb Good Enough for You? | | 7 | Motley Fool |
| 27.01.
| Bristol-Myers Squibb Meets on the Top Line, Misses Where it Counts | | 5 | Motley Fool |
| 26.01.
| Bristol-Myers Squibb's CEO Discusses Q4 2011 Results - Earnings Call Transcript | | 3 | Seeking Alpha |
| 26.01.
| Bristol-Myers Misses Estimates on Costs to Sell New Drugs | | 1 | Business Week |
| 26.01.
| Bristol-Myers Misses on All Fronts | | 1 | Zacks |
| 26.01.
| ROUNDUP: Bristol-Myers Squibb Q4 Profit Rises, But Misses Estimates | | 53 | AFX News |
| NEW YORK CITY (dpa-AFX) - Biopharmaceutical firm Bristol-Myers Squibb Co.
(BMY) Thursday reported a higher fourth-quarter profit, as strong sales of type
2 diabetes drug Onglyza/Kombiglyze...
Mehr lesen zu:
ROUNDUP: Bristol-Myers Squibb Q4 Profit Rises, But Misses Estimates | |
